Lb Pharmaceuticals (LBRX) Enterprise Value (2024 - 2026)

Lb Pharmaceuticals' Enterprise Value history runs 3 years deep, the most recent figure standing at -$365.6 million for Q1 2026.

• In Q1 2026, Enterprise Value changed N/A year-over-year to -$365.6 million; the TTM figure through Mar 2026 stood at -$365.6 million (changed N/A YoY), while the FY2025 annual figure was -$295.2 million, down 954.37% from the prior year.
• Enterprise Value was -$365.6 million for Q1 2026 at Lb Pharmaceuticals, down from -$295.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$28.0 million in Q4 2024 to a low of -$365.6 million in Q1 2026.
• Historically, Enterprise Value has averaged -$250.8 million across 3 years, with a median of -$304.8 million in 2025.
• Biggest YoY gain for Enterprise Value was 954.37% in 2025; the steepest drop was 954.37% in 2025.
• A 3-year view of Enterprise Value shows it stood at -$28.0 million in 2024, then sank by 954.37% to -$295.2 million in 2025, then declined by 23.85% to -$365.6 million in 2026.
• The last three Enterprise Value figures came in at -$365.6 million (Q1 2026), -$295.2 million (Q4 2025), and -$314.5 million (Q3 2025), per Business Quant data.